市場調查報告書
商品編碼
1463655
南美洲和中美洲腦脊髓液管理市場預測至 2030 年 - 區域分析 - 按產品(腦脊髓液分流器和腦脊髓液引流系統)和最終用戶(醫院、診所、門診手術中心等)South & Central America Cerebrospinal Fluid Management Market Forecast to 2030 - Regional Analysis - by Product (CSF Shunts and CSF Drainage Systems) and End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others) |
2022年,中南美洲腦脊髓液管理市場價值為9,252萬美元,預計2030年將達到1.2,389億美元;預計 2022 年至 2030 年CAGR為 3.7%。
神經系統疾病治療中對腦脊髓液管理的日益關注推動了南美洲和中美洲腦脊髓液管理市場的發展
腦脊髓液參數作為成年患者神經系統疾病的生物標記被廣泛評估。腦脊髓液中循環的 microRNA 是一類有前景的生物標記物,可用於診斷各種神經系統疾病。帕金森氏症 (PD)、阿茲海默症 (AD)、癲癇和癲癇等神經系統疾病通常會導致腦脊髓液參數改變。根據《自然》雜誌發表的一篇文章,與正常人相比,被診斷為 PD 的患者中發現 76 種腦脊髓液蛋白在結構上發生了變化。該研究還表明,這些腦脊髓液蛋白可用作診斷或治療該疾病的生物標記。 PD 是一種與認知障礙和運動功能喪失相關的神經退化性疾病。根據世界衛生組織 (WHO) 2022 年發布的報告,帕金森氏症的盛行率在過去 25 年中加倍,影響了全球約 1% 的 60 歲以上人口。同樣,患有癲癇發作或癲癇持續狀態的患者的一些腦脊髓液參數(例如蛋白質和乳酸水平)也會發生變化。因此,利用腦脊髓液參數治療癲癇發作或癲癇的各種研發活動正在進行中。此外,儘管市場上有各種使用CSF檢測阿茲海默症的CSF測定法,但對用於檢測和治療目的的生物標記的需求尚未得到滿足。隨著阿茲海默症和帕金森氏症病例的增加,對腦脊髓液管理設備的需求也隨之增加,因為腦脊髓液漏的病例可能會增加。因此,神經系統疾病盛行率的上升正在推動使用腦脊髓液管理產品治療這些疾病的研發活動。
南美洲和中美洲腦脊髓液管理市場概述
南美洲和中美洲的腦脊髓液管理市場分為巴西、阿根廷以及南美洲和中美洲的其他地區。由於醫療設備進口的增加、需要先進醫療技術的醫療保健系統的不斷發展以及老年人口的不斷成長,預計該地區的市場將出現成長。
南美洲及中美洲腦脊髓液管理市場收入及 2030 年預測(百萬美元)
南美洲和中美洲腦脊髓液管理市場細分
南美洲和中美洲腦脊髓液管理市場分為產品、最終用戶和國家。
根據產品,南美洲和中美洲腦脊髓液管理市場分為腦脊髓液分流器和腦脊髓液引流系統。 2022 年,CCS 分流器細分市場將佔據更大的市場。
根據最終用戶,南美洲和中美洲腦脊髓液管理市場分為醫院、診所、門診手術中心等。 2022 年,醫院細分市場佔據最大市場佔有率。
根據國家/地區,南美洲和中美洲腦脊髓液管理市場分為巴西、阿根廷以及南美洲和中美洲其他地區。 2022 年,巴西在南美洲和中美洲腦脊髓液管理市場佔有率中佔據主導地位。
B. Braun SE、Integra LifeSciences Holdings Corp、Medtronic Plc 和 Spiegelberg GmbH & Co KG 是南美洲和中美洲腦脊髓液管理市場的一些領先公司。
The South & Central America cerebrospinal fluid management market was valued at US$ 92.52 million in 2022 and is expected to reach US$ 123.89 million by 2030; it is estimated to grow at a CAGR of 3.7% from 2022 to 2030.
Increasing Focus on CSF Management in Neurological Disease Treatments Fuels the South & Central America Cerebrospinal Fluid Management Market
CSF parameters are extensively evaluated as biomarkers of neurological disorders in adult patients. Circulating microRNAs in CSF are a promising class of biomarkers for the diagnosis of various neurological diseases. Neurological disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), epilepsy, and seizures often lead to altered CSF parameters. According to an article published in Nature, 76 CSF proteins were found to be structurally altered in patients that were diagnosed with PD when compared to normal individuals. The study also suggests that these CSF proteins can be used as biomarkers for the diagnosis or treatment of the disease. PD is a neurodegenerative disease associated with loss of cognitive impairment and motor function. According to the World Health Organization (WHO) report published in 2022, the prevalence of PD has doubled in the last 25 years, affecting ~1% of the global population aged more than 60 years. Similarly, a few of the CSF parameters such as protein and lactate levels are altered in patients suffering from seizure or status epilepticus. Therefore, various R&D activities are going on for using CSF parameters in the treatment of seizures or epilepsy. Further, despite the availability of various CSF assays for the detection of Alzheimer's disease using CSF in the market, there are unmet needs for biomarkers for detection and treatment purposes. As the detection of cases of Alzheimer's disease and PD increases, there is increase in demand for CSF management devices as the cases of CSF leaks may increases. Therefore, a rise in the prevalence of neurological disorders is fueling the research and development activities for the use of CSF management products in the treatment of these disorders.
South & Central America Cerebrospinal Fluid Management Market Overview
The cerebrospinal fluid management market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The growth of the market in the region is expected due to several opportunities offered by increasing import of medical devices, growing developments of healthcare systems that demand advanced medical technologies and growing geriatric population.
South & Central America Cerebrospinal Fluid Management Market Revenue and Forecast to 2030 (US$ Mn)
South & Central America Cerebrospinal Fluid Management Market Segmentation
The South & Central America cerebrospinal fluid management market is segmented into product, end user and country.
Based on product, the South & Central America cerebrospinal fluid management market is bifurcated into CSF shunts and CSF drainage systems. The CSF shunts segment held a larger market share in 2022.
Based on end user, the South & Central America cerebrospinal fluid management market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest market share in 2022.
Based on country, the South & Central America cerebrospinal fluid management market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America cerebrospinal fluid management market share in 2022.
B. Braun SE, Integra LifeSciences Holdings Corp, Medtronic Plc, and Spiegelberg GmbH & Co KG are some of the leading companies operating in the South & Central America cerebrospinal fluid management market.